<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01559935</url>
  </required_header>
  <id_info>
    <org_study_id>1108011903</org_study_id>
    <nct_id>NCT01559935</nct_id>
  </id_info>
  <brief_title>Carfilzomib, Clarithromycin (Biaxin®), Lenalidomide (Revlimid®), and Dexamethasone (Decadron®) [Car-BiRD] Therapy for Subjects With Multiple Myeloma</brief_title>
  <acronym>CarBiRD</acronym>
  <official_title>A Phase II Study of Sequential Carfilzomib, Clarithromycin (Biaxin®), Lenalidomide (Revlimid®), and Dexamethasone (Decadron®) [Car-BiRD] Therapy for Subjects With Newly Diagnosed Multiple Myeloma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Weill Medical College of Cornell University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Onyx Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Weill Medical College of Cornell University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety and effectiveness of an investigational
      new drug called carfilzomib, in combination with dexamethasone in subjects with newly
      diagnosed multiple myeloma followed by treatment with a combination of drugs clarithromycin
      (Biaxin®), lenalidomide (Revlimid®) and dexamethasone (Decadron®) [BiRD] then lenalidomide
      alone.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      While new anti-myeloma therapies such as bortezomib and immunomodulatory drugs have been
      developed, multiple myeloma remains an incurable malignancy. Given that obtaining a complete
      remission (CR) with therapy will allow patients with newly diagnosed multiple myeloma to
      enjoy a higher quality of life and longer duration of freedom from disease symptoms, finding
      an optimally effective and well-tolerated regimen is imperative.

      The robust overall response rate of 91% with the BiRD regimen for patients with newly
      diagnosed multiple myeloma is encouraging and we believe that by adding carfilzomib the
      overall response rate and CR rate can be improved. As carfilzomib has proven efficacy in
      myeloma and in patient's who have relapsed on bortezomib, we anticipate that it will
      synergize with the previous BiRD regimen to induce greater reduction of tumor burden overall.

      The primary endpoints include best response rate, toxicities, progression free survival,
      event free survival, and overall survival. In those patients who are eligible for autologous
      stem cell transplantation, we will also study the effect of carfilzomib on CD 34+ stem cell
      yield following mobilization.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">March 2012</start_date>
  <completion_date type="Anticipated">March 2022</completion_date>
  <primary_completion_date type="Actual">June 7, 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Response to Car-BiRD Treatment.</measure>
    <time_frame>From baseline to best response, up to 116 weeks.</time_frame>
    <description>The best response for all patients who had at least one dose of drug was measured.
Response categories:
Stringent Complete Response (sCR), Complete Remission(CR), Very Good Partial Remission(VGPR), Partial Remission (PR), Progressive Disease (PD), Stable Disease (SD).
The response is evaluated based on the IMWG criteria.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Event Free Survival</measure>
    <time_frame>From date of study enrollment until the date of removal of study due to progression of disease, toxicity or withdrawal of consent, up to 1222 days.</time_frame>
    <description>an event is defined by coming off protocol for any reason, including progression of disease, lack of disease response, regimen intolerability, withdrawal of consent or death.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MRD Negativity Following CarBiRD Regimen</measure>
    <time_frame>From start of study up to Revlimid Maintenance Cycle 4.</time_frame>
    <description>Minimal Residual Disease (MRD) was assessed for all participants as soon as they achieved CR/sCR, regardless of what phase they were on.
MRD negativity is defined as the complete absence of plasma cells on bone marrow biopsy.
MRD positivity is defined as the presence of residual plasma cells (&lt;5%) on bone marrow biopsy.
The IMWG criteria were used to determine CR and sCR.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival</measure>
    <time_frame>From start of study drug until first incidence of progression, up to 1222 days.</time_frame>
    <description>Progression was defined using the IMWG criteria.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stem Cells Collection</measure>
    <time_frame>At the end of the Car Phase, prior to the start of the BiRD Phase, on average after 162 days.</time_frame>
    <description>At the end of the Car Phase, all participants underwent stem cell collection.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">74</enrollment>
  <condition>Multiple Myeloma</condition>
  <arm_group>
    <arm_group_label>Car-BiRD Therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Carfilzomib, Clarithromycin (Biaxin®), Lenalidomide (Revlimid®), and Dexamethasone (Decadron®) [Car-BiRD]</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>carfilzomib</intervention_name>
    <description>45 mg/m2 IV on days 1, 2, 8, 9, 15 and 16 of each 28 day cycles.</description>
    <arm_group_label>Car-BiRD Therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone</intervention_name>
    <description>20 mg orally on days 1, 2, 8, 9, 15 and 16 of a 28 day cycle, while receiving carfilzomib.</description>
    <arm_group_label>Car-BiRD Therapy</arm_group_label>
    <other_name>DECADRON®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clarithromycin</intervention_name>
    <description>500 mg twice a day for each 28 day cycle of BiRD treatment. BiRD begins after carfilzomib treatment has been completed.</description>
    <arm_group_label>Car-BiRD Therapy</arm_group_label>
    <other_name>Biaxin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lenalidomide</intervention_name>
    <description>25 mg orally days 1-21 for each 28 day cycle of BiRD treatment. BiRD begins after carfilzomib treatment has been completed.</description>
    <arm_group_label>Car-BiRD Therapy</arm_group_label>
    <other_name>Revlimid</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone</intervention_name>
    <description>40 mg orally on days 1, 8, 15 and 22 of each 28 day cycle of BiRD treatment. BiRD begins after carfilzomib treatment has been completed.</description>
    <arm_group_label>Car-BiRD Therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lenalidomide</intervention_name>
    <description>10 mg orally on days 1-21 or each 28 day cycle of maintenance. Maintenance begins after BiRD treatment has been completed.</description>
    <arm_group_label>Car-BiRD Therapy</arm_group_label>
    <other_name>Revlimid</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject must voluntarily sign and understand written informed consent.

          -  Subject is ≥ 18 years at the time of signing the consent form.

          -  Subject has histologically confirmed multiple myeloma that has never before been
             treated.

          -  Subject had no anti-myeloma therapy within 14 days prior to initiation of study
             treatment except for corticosteroids with a maximum allowed dosage equivalent to three
             pulses of dexamethasone (40mg daily for 4 days equals one pulse). Patients may have
             received prior adjuvant antiresorptive therapy (i.e., pamidronate or zoledronic acid)
             as routine care, or radiation therapy as palliation for pain and/or spinal cord
             compression.

          -  Subject has measurable disease as defined by &gt; 0.5 g/dL serum monoclonal protein, &gt; 10
             mg/dL involved serum free light chain (either kappa or lambda) provided that the serum
             free light chain ratio is abnormal, &gt; 0.2 g/24 hrs urinary M-protein excretion, and/or
             measurable plasmacytoma(s) of at least 1cm in greatest dimension as measured by either
             CT scanning or MRI.

          -  Subject has a Karnofsky performance status ≥ 60% (&gt; 50% if due to bony involvement of
             myeloma (see Appendix VI).

          -  Subject is able to take prophylactic anticoagulation as detailed in section 9.1
             (patients intolerant to aspirin may use warfarin or low molecular weight heparin).

          -  Subject is registered into the mandatory RevAssist® program, and is willing and able
             to comply with the requirements of RevAssist® program.

          -  If subject is a female of childbearing potential (FCBP),† she must have a negative
             serum or urine pregnancy test with a sensitivity of at least 25 mIU/mL within 10 - 14
             days prior to and again within 24 hours of prescribing lenalidomide (prescriptions
             must be filled within 7 days) and must either commit to continued abstinence from
             heterosexual intercourse or begin TWO acceptable methods of birth control, one highly
             effective method and one additional effective method AT THE SAME TIME, at least 28
             days before she starts taking lenalidomide. FCBP must also agree to ongoing pregnancy
             testing. Men must agree to use a latex condom during sexual contact with females of
             child bearing potential even if they have had a successful vasectomy.

          -  Subjects must meet the following laboratory parameters:

               -  Absolute neutrophil count (ANC) ≥750 cells/mm3 (1.0 x 109/L)

               -  Hemoglobin ≥ 7 g/dL

               -  Platelet count ≥ 30,000/mm3 (75 x 109/L)

               -  Serum SGOT/AST &lt; 3.0 x upper limits of normal (ULN)

               -  Serum SGPT/ALT &lt; 3.0 x upper limits of normal (ULN)

               -  Serum creatinine &lt; 2.5 mg/dL (221 µmol/L)

               -  Serum total bilirubin &lt; 2.0 mg/dL (34 µmol/L)

        Exclusion Criteria:

          -  Subject has immeasurable MM (no measurable monoclonal protein, free light chains in
             blood or urine, or measureable plasmacytoma on radiologic scanning).

          -  Subject has a prior history of other malignancies unless disease free for ≥ 5 years,
             except for basal cell or squamous cell carcinoma of the skin, carcinoma in situ of the
             cervix or breast, or localized prostate cancer with Gleason score &lt; 7 with stable
             prostate specific antigen (PSA) levels.

          -  Subject has had myocardial infarction within 6 months prior to enrollment , or
             NYHA(New York Hospital Association) Class III or IV heart failure, Ejection Fraction &lt;
             35%, uncontrolled angina, severe uncontrolled ventricular arrhythmias,
             electrocardiographic evidence of acute ischemia or active conduction system
             abnormalities.

          -  Female subject who is pregnant or lactating.

          -  Subject has known HIV infection

          -  Subject has known active hepatitis B or hepatitis C infection.

          -  Subject has active viral or bacterial infections or any coexisting medical problem
             that would significantly increase the risks of this treatment program.

          -  Subject has known hypersensitivity to dexamethasone, clarithromycin, lenalidomide,
             thalidomide, allopurinol, or carfilzomib.

          -  Subject has a history of thromboembolic event within the past 4 weeks prior to
             enrollment.

          -  Subject has any clinically significant medical or psychiatric disease or condition
             that, in the Investigator's opinion, may interfere with protocol adherence or a
             subject's ability to give informed consent.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Adriana Rossi, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Weill Medical College of Cornell University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Weill Cornell Medical College</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 16, 2012</study_first_submitted>
  <study_first_submitted_qc>March 19, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 21, 2012</study_first_posted>
  <results_first_submitted>February 1, 2017</results_first_submitted>
  <results_first_submitted_qc>February 1, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">March 22, 2017</results_first_posted>
  <last_update_submitted>April 27, 2018</last_update_submitted>
  <last_update_submitted_qc>April 27, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 1, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Multiple Myeloma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Lenalidomide</mesh_term>
    <mesh_term>Thalidomide</mesh_term>
    <mesh_term>BB 1101</mesh_term>
    <mesh_term>Clarithromycin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>Two subjects were ineligible and therefore never started treatment.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Car-BiRD Therapy</title>
          <description>Carfilzomib, Clarithromycin (Biaxin®), Lenalidomide (Revlimid®), and Dexamethasone (Decadron®) [Car-BiRD]
Car Phase:
carfilzomib: 45 mg/m2 IV on days 1, 2, 8, 9, 15 and 16 of each 28 day cycles. Dexamethasone: 20 mg orally on days 1, 2, 8, 9, 15 and 16 of a 28 day cycle, while receiving carfilzomib.
BiRD Phase:
Clarithromycin: 500 mg twice a day for each 28 day cycle of BiRD treatment. BiRD begins after carfilzomib treatment has been completed.
Lenalidomide: 25 mg orally days 1-21 for each 28 day cycle of BiRD treatment. BiRD begins after carfilzomib treatment has been completed.
Dexamethasone: 40 mg orally on days 1, 8, 15 and 22 of each 28 day cycle of BiRD treatment. BiRD begins after carfilzomib treatment has been completed.
Maintenance Phase:
Lenalidomide: 10 mg orally on days 1-21 or each 28 day cycle of maintenance. Maintenance begins after BiRD treatment has been completed.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Car Phase</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="72"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="58"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Toxicity</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Per protocol</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Insurance</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>non-compliance</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>BiRD Phase</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="58"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="54"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Toxicity</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Maintenance Phase</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="54"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="54"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Remains on study</title>
              <participants_list>
                <participants group_id="P1" count="28"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Toxicity</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Non-compliance</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>72 subjects started the Car Phase of the CarBiRD therapy. 58 subjects started the BiRD Phase of the CarBiRD therapy. 54 subjects started the Maintenance Phase of the CarBiRD therapy. A detailed explanation of those numbers is provided in the participant flow.</population>
      <group_list>
        <group group_id="B1">
          <title>Car-BiRD Therapy</title>
          <description>Carfilzomib, Clarithromycin (Biaxin®), Lenalidomide (Revlimid®), and Dexamethasone (Decadron®) [Car-BiRD]
Car Phase:
carfilzomib: 45 mg/m2 IV on days 1, 2, 8, 9, 15 and 16 of each 28 day cycles. Dexamethasone: 20 mg orally on days 1, 2, 8, 9, 15 and 16 of a 28 day cycle, while receiving carfilzomib.
BiRD Phase:
Clarithromycin: 500 mg twice a day for each 28 day cycle of BiRD treatment. BiRD begins after carfilzomib treatment has been completed.
Lenalidomide: 25 mg orally days 1-21 for each 28 day cycle of BiRD treatment. BiRD begins after carfilzomib treatment has been completed.
Dexamethasone: 40 mg orally on days 1, 8, 15 and 22 of each 28 day cycle of BiRD treatment. BiRD begins after carfilzomib treatment has been completed.
Maintenance Phase:
Lenalidomide: 10 mg orally on days 1-21 or each 28 day cycle of maintenance. Maintenance begins after BiRD treatment has been completed.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="72"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <population>72 subjects started the Car Phase of the CarBiRD therapy. 58 subjects reached the BiRD Phase of the CarBiRD therapy. 54 subjects reached the Maintenance Phase of the CarBiRD therapy. A detailed explanation of those numbers is provided in the participant flow.</population>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <title>Car Phase</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="72"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="60.4" lower_limit="42" upper_limit="85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BiRD Phase</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="58"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="59.6" lower_limit="42" upper_limit="85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Maintenance Phase</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="54"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="59.2" lower_limit="42" upper_limit="79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <population>72 subjects started the Car Phase of the CarBiRD therapy. 58 subjects reached the BiRD Phase of the CarBiRD therapy. 54 subjects reached the Maintenance Phase of the CarBiRD therapy. A detailed explanation of those numbers is provided in the participant flow.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Car Phase</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="72"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="29"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BiRD Phase</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="58"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Maintenance Phase</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="54"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <population>72 subjects started the Car Phase of the CarBiRD therapy. 58 subjects started the BiRD Phase of the CarBiRD therapy. 54 subjects started the Maintenance Phase of the CarBiRD therapy. A detailed explanation of those numbers is provided in the participant flow.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Car Phase</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="72"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="61"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BiRD Phase</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="58"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="48"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Maintenance Phase</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="54"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="45"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <population>72 subjects started the Car Phase of the CarBiRD therapy. 58 subjects started the BiRD Phase of the CarBiRD therapy. 54 subjects started the Maintenance Phase of the CarBiRD therapy. A detailed explanation of those numbers is provided in the participant flow.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Car Phase</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="72"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="29"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BiRD Phase</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="58"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Maintenance Phase</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="54"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Response to Car-BiRD Treatment.</title>
        <description>The best response for all patients who had at least one dose of drug was measured.
Response categories:
Stringent Complete Response (sCR), Complete Remission(CR), Very Good Partial Remission(VGPR), Partial Remission (PR), Progressive Disease (PD), Stable Disease (SD).
The response is evaluated based on the IMWG criteria.</description>
        <time_frame>From baseline to best response, up to 116 weeks.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Car-BiRD Therapy</title>
            <description>Carfilzomib, Clarithromycin (Biaxin®), Lenalidomide (Revlimid®), and Dexamethasone (Decadron®) [Car-BiRD]
Car Phase:
carfilzomib: 45 mg/m2 IV on days 1, 2, 8, 9, 15 and 16 of each 28 day cycles. Dexamethasone: 20 mg orally on days 1, 2, 8, 9, 15 and 16 of a 28 day cycle, while receiving carfilzomib.
BiRD Phase:
Clarithromycin: 500 mg twice a day for each 28 day cycle of BiRD treatment. BiRD begins after carfilzomib treatment has been completed.
Lenalidomide: 25 mg orally days 1-21 for each 28 day cycle of BiRD treatment. BiRD begins after carfilzomib treatment has been completed.
Dexamethasone: 40 mg orally on days 1, 8, 15 and 22 of each 28 day cycle of BiRD treatment. BiRD begins after carfilzomib treatment has been completed.
Maintenance Phase:
Lenalidomide: 10 mg orally on days 1-21 or each 28 day cycle of maintenance. Maintenance begins after BiRD treatment has been completed.</description>
          </group>
        </group_list>
        <measure>
          <title>Response to Car-BiRD Treatment.</title>
          <description>The best response for all patients who had at least one dose of drug was measured.
Response categories:
Stringent Complete Response (sCR), Complete Remission(CR), Very Good Partial Remission(VGPR), Partial Remission (PR), Progressive Disease (PD), Stable Disease (SD).
The response is evaluated based on the IMWG criteria.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="72"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>sCR/CR</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>VGPR</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PR</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SD</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PD</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not Evaluable</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Event Free Survival</title>
        <description>an event is defined by coming off protocol for any reason, including progression of disease, lack of disease response, regimen intolerability, withdrawal of consent or death.</description>
        <time_frame>From date of study enrollment until the date of removal of study due to progression of disease, toxicity or withdrawal of consent, up to 1222 days.</time_frame>
        <population>44 participants analyzed out of the 72 participants initially enrolled in the study. 28 participants are active and therefore have not experienced any events leading to removal from study.</population>
        <group_list>
          <group group_id="O1">
            <title>Car-BiRD Therapy</title>
            <description>Carfilzomib, Clarithromycin (Biaxin®), Lenalidomide (Revlimid®), and Dexamethasone (Decadron®) [Car-BiRD]
Car Phase:
carfilzomib: 45 mg/m2 IV on days 1, 2, 8, 9, 15 and 16 of each 28 day cycles. Dexamethasone: 20 mg orally on days 1, 2, 8, 9, 15 and 16 of a 28 day cycle, while receiving carfilzomib.
BiRD Phase:
Clarithromycin: 500 mg twice a day for each 28 day cycle of BiRD treatment. BiRD begins after carfilzomib treatment has been completed.
Lenalidomide: 25 mg orally days 1-21 for each 28 day cycle of BiRD treatment. BiRD begins after carfilzomib treatment has been completed.
Dexamethasone: 40 mg orally on days 1, 8, 15 and 22 of each 28 day cycle of BiRD treatment. BiRD begins after carfilzomib treatment has been completed.
Maintenance Phase:
Lenalidomide: 10 mg orally on days 1-21 or each 28 day cycle of maintenance. Maintenance begins after BiRD treatment has been completed.</description>
          </group>
        </group_list>
        <measure>
          <title>Event Free Survival</title>
          <description>an event is defined by coming off protocol for any reason, including progression of disease, lack of disease response, regimen intolerability, withdrawal of consent or death.</description>
          <population>44 participants analyzed out of the 72 participants initially enrolled in the study. 28 participants are active and therefore have not experienced any events leading to removal from study.</population>
          <units>Days</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="44"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="401.5" lower_limit="18" upper_limit="1222"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>MRD Negativity Following CarBiRD Regimen</title>
        <description>Minimal Residual Disease (MRD) was assessed for all participants as soon as they achieved CR/sCR, regardless of what phase they were on.
MRD negativity is defined as the complete absence of plasma cells on bone marrow biopsy.
MRD positivity is defined as the presence of residual plasma cells (&lt;5%) on bone marrow biopsy.
The IMWG criteria were used to determine CR and sCR.</description>
        <time_frame>From start of study up to Revlimid Maintenance Cycle 4.</time_frame>
        <population>28 participants achieved CR or sCR.</population>
        <group_list>
          <group group_id="O1">
            <title>Car-BiRD Therapy</title>
            <description>Carfilzomib, Clarithromycin (Biaxin®), Lenalidomide (Revlimid®), and Dexamethasone (Decadron®) [Car-BiRD]
Car Phase:
carfilzomib: 45 mg/m2 IV on days 1, 2, 8, 9, 15 and 16 of each 28 day cycles. Dexamethasone: 20 mg orally on days 1, 2, 8, 9, 15 and 16 of a 28 day cycle, while receiving carfilzomib.
BiRD Phase:
Clarithromycin: 500 mg twice a day for each 28 day cycle of BiRD treatment. BiRD begins after carfilzomib treatment has been completed.
Lenalidomide: 25 mg orally days 1-21 for each 28 day cycle of BiRD treatment. BiRD begins after carfilzomib treatment has been completed.
Dexamethasone: 40 mg orally on days 1, 8, 15 and 22 of each 28 day cycle of BiRD treatment. BiRD begins after carfilzomib treatment has been completed.
Maintenance Phase:
Lenalidomide: 10 mg orally on days 1-21 or each 28 day cycle of maintenance. Maintenance begins after BiRD treatment has been completed.</description>
          </group>
        </group_list>
        <measure>
          <title>MRD Negativity Following CarBiRD Regimen</title>
          <description>Minimal Residual Disease (MRD) was assessed for all participants as soon as they achieved CR/sCR, regardless of what phase they were on.
MRD negativity is defined as the complete absence of plasma cells on bone marrow biopsy.
MRD positivity is defined as the presence of residual plasma cells (&lt;5%) on bone marrow biopsy.
The IMWG criteria were used to determine CR and sCR.</description>
          <population>28 participants achieved CR or sCR.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>MRD positive</title>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>MRD negative</title>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Evaluable</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Progression Free Survival</title>
        <description>Progression was defined using the IMWG criteria.</description>
        <time_frame>From start of study drug until first incidence of progression, up to 1222 days.</time_frame>
        <population>21 participants had an incidence of progression.</population>
        <group_list>
          <group group_id="O1">
            <title>Car-BiRD Therapy</title>
            <description>Carfilzomib, Clarithromycin (Biaxin®), Lenalidomide (Revlimid®), and Dexamethasone (Decadron®) [Car-BiRD]
Car Phase:
carfilzomib: 45 mg/m2 IV on days 1, 2, 8, 9, 15 and 16 of each 28 day cycles. Dexamethasone: 20 mg orally on days 1, 2, 8, 9, 15 and 16 of a 28 day cycle, while receiving carfilzomib.
BiRD Phase:
Clarithromycin: 500 mg twice a day for each 28 day cycle of BiRD treatment. BiRD begins after carfilzomib treatment has been completed.
Lenalidomide: 25 mg orally days 1-21 for each 28 day cycle of BiRD treatment. BiRD begins after carfilzomib treatment has been completed.
Dexamethasone: 40 mg orally on days 1, 8, 15 and 22 of each 28 day cycle of BiRD treatment. BiRD begins after carfilzomib treatment has been completed.
Maintenance Phase:
Lenalidomide: 10 mg orally on days 1-21 or each 28 day cycle of maintenance. Maintenance begins after BiRD treatment has been completed.</description>
          </group>
        </group_list>
        <measure>
          <title>Progression Free Survival</title>
          <description>Progression was defined using the IMWG criteria.</description>
          <population>21 participants had an incidence of progression.</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.3" lower_limit="2.3" upper_limit="40.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Stem Cells Collection</title>
        <description>At the end of the Car Phase, all participants underwent stem cell collection.</description>
        <time_frame>At the end of the Car Phase, prior to the start of the BiRD Phase, on average after 162 days.</time_frame>
        <population>58 participants reached the end of the Car Phase. From those 58 participants, 52 were collected, 5 participants declined stem cell collection and 1 participant's results were not evaluable.</population>
        <group_list>
          <group group_id="O1">
            <title>Car-BiRD Therapy</title>
            <description>Carfilzomib, Clarithromycin (Biaxin®), Lenalidomide (Revlimid®), and Dexamethasone (Decadron®) [Car-BiRD]
Car Phase:
carfilzomib: 45 mg/m2 IV on days 1, 2, 8, 9, 15 and 16 of each 28 day cycles. Dexamethasone: 20 mg orally on days 1, 2, 8, 9, 15 and 16 of a 28 day cycle, while receiving carfilzomib.
BiRD Phase:
Clarithromycin: 500 mg twice a day for each 28 day cycle of BiRD treatment. BiRD begins after carfilzomib treatment has been completed.
Lenalidomide: 25 mg orally days 1-21 for each 28 day cycle of BiRD treatment. BiRD begins after carfilzomib treatment has been completed.
Dexamethasone: 40 mg orally on days 1, 8, 15 and 22 of each 28 day cycle of BiRD treatment. BiRD begins after carfilzomib treatment has been completed.
Maintenance Phase:
Lenalidomide: 10 mg orally on days 1-21 or each 28 day cycle of maintenance. Maintenance begins after BiRD treatment has been completed.</description>
          </group>
        </group_list>
        <measure>
          <title>Stem Cells Collection</title>
          <description>At the end of the Car Phase, all participants underwent stem cell collection.</description>
          <population>58 participants reached the end of the Car Phase. From those 58 participants, 52 were collected, 5 participants declined stem cell collection and 1 participant's results were not evaluable.</population>
          <units>Number of stem cells collected per Kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="52"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12854635" spread="5388946.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>Collection of adverse events is ongoing as 28 participants are still on trial.
For the Car Phase, every adverse event not present at baseline was reported. For the BiRD and Maintenance phases, adverse events were only reported if it was a new occurrence (not present in the previous phase) or if the grade of the event increased.
Grading was done using the CTCAE 4.0.</desc>
      <group_list>
        <group group_id="E1">
          <title>Car-BiRD Therapy</title>
          <description>Carfilzomib, Clarithromycin (Biaxin®), Lenalidomide (Revlimid®), and Dexamethasone (Decadron®) [Car-BiRD]
Car Phase:
carfilzomib: 45 mg/m2 IV on days 1, 2, 8, 9, 15 and 16 of each 28 day cycles. Dexamethasone: 20 mg orally on days 1, 2, 8, 9, 15 and 16 of a 28 day cycle, while receiving carfilzomib.
BiRD Phase:
Clarithromycin: 500 mg twice a day for each 28 day cycle of BiRD treatment. BiRD begins after carfilzomib treatment has been completed.
Lenalidomide: 25 mg orally days 1-21 for each 28 day cycle of BiRD treatment. BiRD begins after carfilzomib treatment has been completed.
Dexamethasone: 40 mg orally on days 1, 8, 15 and 22 of each 28 day cycle of BiRD treatment. BiRD begins after carfilzomib treatment has been completed.
Maintenance Phase:
Lenalidomide: 10 mg orally on days 1-21 or each 28 day cycle of maintenance. Maintenance begins after BiRD treatment has been completed.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="72"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>atrial fibrilation</sub_title>
                <description>car phase</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>massive heart attack</sub_title>
                <description>car phase</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>acute coronary syndrome</sub_title>
                <description>BiRD phase</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>cardiac chest pain</sub_title>
                <description>Maintenance phase</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="54"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>diarrhea</sub_title>
                <description>Maintenance phase</description>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="54"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>abnominal infection</sub_title>
                <description>car phase</description>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>lung infection</sub_title>
                <description>car phase</description>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>URI</sub_title>
                <description>car phase</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>UTI</sub_title>
                <description>car phase</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>lung infection</sub_title>
                <description>BiRD phase</description>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>lung infection</sub_title>
                <description>Maintenance phase</description>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="54"/>
              </event>
              <event>
                <sub_title>acute kidney infection</sub_title>
                <description>Maintenance phase</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="54"/>
              </event>
              <event>
                <sub_title>enterocolitis infection</sub_title>
                <description>Maintenance phase</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="54"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>fall</sub_title>
                <description>car phase</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="72"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>increased creatinine</sub_title>
                <description>car phase</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>dehydration</sub_title>
                <description>car phase</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>creatinine increase</sub_title>
                <description>Maintenance phase</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="54"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>femur fracture</sub_title>
                <description>car phase</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>spinal fracture</sub_title>
                <description>car phase</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>back pain</sub_title>
                <description>car phase</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>non-cardiac chest pain</sub_title>
                <description>BiRD phase</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>abdominal pain (small intestinal obstruction)</sub_title>
                <description>BiRD phase</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>non-cardiac chest pain</sub_title>
                <description>Maintenance phase</description>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="54"/>
              </event>
              <event>
                <sub_title>spinal cord compression</sub_title>
                <description>Maintenance phase</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="54"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>thyroid cancer</sub_title>
                <description>car phase</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>secondary malignancy</sub_title>
                <description>Maintenance phase</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="54"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>syncope</sub_title>
                <description>car phase</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>confusion</sub_title>
                <description>car phase</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="72"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>dyspnea</sub_title>
                <description>car phase</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>pulmonary embolism</sub_title>
                <description>car phase</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="72"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>surgical procedure</sub_title>
                <description>car phase</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="72"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>fever</sub_title>
                <description>car phase</description>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>thromboembolic event</sub_title>
                <description>Maintenance phase</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="54"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="72" subjects_at_risk="72"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>anemia</sub_title>
                <description>Car phase</description>
                <counts group_id="E1" subjects_affected="52" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>thrombocytopenia</sub_title>
                <description>Car phase</description>
                <counts group_id="E1" subjects_affected="64" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>neutropenia</sub_title>
                <description>Car phase</description>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>leukopenia</sub_title>
                <description>Car phase</description>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>lymphopenia</sub_title>
                <description>Car phase</description>
                <counts group_id="E1" subjects_affected="69" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>neutropenia</sub_title>
                <description>BiRD phase</description>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>leukopenia</sub_title>
                <description>BiRD phase</description>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>lymphopenia</sub_title>
                <description>BiRD phase</description>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>thrombocytopenia</sub_title>
                <description>Maintenance phase</description>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="54"/>
              </event>
              <event>
                <sub_title>neutropenia</sub_title>
                <description>Maintenance phase</description>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="54"/>
              </event>
              <event>
                <sub_title>leukopenia</sub_title>
                <description>Maintenance phase</description>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="54"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>high BNP</sub_title>
                <description>Car phase</description>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>bradycardia</sub_title>
                <description>Maintenance phase</description>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="54"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>blurry vision</sub_title>
                <description>Maintenance phase</description>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="54"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>dyspepsia</sub_title>
                <description>Car phase</description>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>constipation</sub_title>
                <description>Car phase</description>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>nausea</sub_title>
                <description>Car phase</description>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>anorexia</sub_title>
                <description>Car phase</description>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>diarhhea</sub_title>
                <description>Car phase</description>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>vomiting</sub_title>
                <description>Car phase</description>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>flatulance</sub_title>
                <description>Car phase</description>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>dyspepsia</sub_title>
                <description>BiRD phase</description>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>constipation</sub_title>
                <description>BiRD phase</description>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>nausea</sub_title>
                <description>BiRD phase</description>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>anorexia</sub_title>
                <description>BiRD phase</description>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>diarhhea</sub_title>
                <description>BiRD phase</description>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>vomiting</sub_title>
                <description>BiRD phase</description>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>dry mouth</sub_title>
                <description>BiRD phase</description>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>flatulance</sub_title>
                <description>BiRD phase</description>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>dyspepsia</sub_title>
                <description>Maintenance phase</description>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="54"/>
              </event>
              <event>
                <sub_title>constipation</sub_title>
                <description>Maintenance phase</description>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="54"/>
              </event>
              <event>
                <sub_title>nausea</sub_title>
                <description>Maintenance phase</description>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="54"/>
              </event>
              <event>
                <sub_title>diarhhea</sub_title>
                <description>Maintenance phase</description>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="54"/>
              </event>
              <event>
                <sub_title>vomiting</sub_title>
                <description>Maintenance phase</description>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="54"/>
              </event>
              <event>
                <sub_title>dry mouth</sub_title>
                <description>Maintenance phase</description>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="54"/>
              </event>
              <event>
                <sub_title>flatulance</sub_title>
                <description>Maintenance phase</description>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="54"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>insomnia</sub_title>
                <description>Car phase</description>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>fatigue</sub_title>
                <description>Car phase</description>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>chills</sub_title>
                <description>Car phase</description>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>insomnia</sub_title>
                <description>BiRD phase</description>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>malaise</sub_title>
                <description>BiRD phase</description>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>fatigue</sub_title>
                <description>BiRD phase</description>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>fatigue</sub_title>
                <description>Maintenance phase</description>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="54"/>
              </event>
              <event>
                <sub_title>gait disturbance</sub_title>
                <description>Maintenance phase</description>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="54"/>
              </event>
              <event>
                <sub_title>hair loss</sub_title>
                <description>Maintenance phase</description>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="54"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>URI</sub_title>
                <description>Car phase</description>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>UTI</sub_title>
                <description>Car phase</description>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>Skin Infection</sub_title>
                <description>Car phase</description>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>URI</sub_title>
                <description>Maintenance phase</description>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="54"/>
              </event>
              <event>
                <sub_title>skin Infection</sub_title>
                <description>Maintenance phase</description>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="54"/>
              </event>
              <event>
                <sub_title>ear infection</sub_title>
                <description>Maintenance phase</description>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="54"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>fall</sub_title>
                <description>Maintenance phase</description>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="54"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>hypocalcemia</sub_title>
                <description>Car phase</description>
                <counts group_id="E1" subjects_affected="56" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>hyponatremia</sub_title>
                <description>Car phase</description>
                <counts group_id="E1" subjects_affected="42" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>hypoglycemia</sub_title>
                <description>Car phase</description>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>hyperglycemia</sub_title>
                <description>Car phase</description>
                <counts group_id="E1" subjects_affected="63" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>hypophosphatemia</sub_title>
                <description>Car phase</description>
                <counts group_id="E1" subjects_affected="35" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>hyperkalemia</sub_title>
                <description>Car phase</description>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>hypokalemia</sub_title>
                <description>Car phase</description>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>hypomagnesemia</sub_title>
                <description>Car phase</description>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>hypermagnesemia</sub_title>
                <description>Car phase</description>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>hypoalbuminemia</sub_title>
                <description>Car phase</description>
                <counts group_id="E1" subjects_affected="39" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>hyperbilirubinemia</sub_title>
                <description>Car phase</description>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>hyperuricemia</sub_title>
                <description>Car phase</description>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>hyperhidrosis</sub_title>
                <description>Car phase</description>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>elevated ALT</sub_title>
                <description>Car phase</description>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>elevated AST</sub_title>
                <description>Car phase</description>
                <counts group_id="E1" subjects_affected="30" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>elevated alkaline phosphatase</sub_title>
                <description>Car phase</description>
                <counts group_id="E1" subjects_affected="34" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>increased creatinine</sub_title>
                <description>Car phase</description>
                <counts group_id="E1" subjects_affected="35" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>hypocalcemia</sub_title>
                <description>BiRD phase</description>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>hypoglycemia</sub_title>
                <description>BiRD phase</description>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>hypokalemia</sub_title>
                <description>BiRD phase</description>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>hypomagnesemia</sub_title>
                <description>BiRD phase</description>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>elevated ALT</sub_title>
                <description>BiRD phase</description>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>ALK increase</sub_title>
                <description>BiRD phase</description>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>increased creatinine</sub_title>
                <description>BiRD phase</description>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>hypocalcemia</sub_title>
                <description>Maintenance phase</description>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="54"/>
              </event>
              <event>
                <sub_title>hypercalcemia</sub_title>
                <description>Maintenance phase</description>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="54"/>
              </event>
              <event>
                <sub_title>hypoglycemia</sub_title>
                <description>Maintenance phase</description>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="54"/>
              </event>
              <event>
                <sub_title>hypophosphatemia</sub_title>
                <description>Maintenance phase</description>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="54"/>
              </event>
              <event>
                <sub_title>hypokalemia</sub_title>
                <description>Maintenance phase</description>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="54"/>
              </event>
              <event>
                <sub_title>hypomagnesemia</sub_title>
                <description>Maintenance phase</description>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="54"/>
              </event>
              <event>
                <sub_title>hypoalbuminemia</sub_title>
                <description>Maintenance phase</description>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="54"/>
              </event>
              <event>
                <sub_title>hyperbilirubinemia</sub_title>
                <description>Maintenance phase</description>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="54"/>
              </event>
              <event>
                <sub_title>hyponatremia</sub_title>
                <description>Maintenance phase</description>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="54"/>
              </event>
              <event>
                <sub_title>hypernatremia</sub_title>
                <description>Maintenance phase</description>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="54"/>
              </event>
              <event>
                <sub_title>elevated ALT</sub_title>
                <description>Maintenance phase</description>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="54"/>
              </event>
              <event>
                <sub_title>elevated AST</sub_title>
                <description>Maintenance phase</description>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="54"/>
              </event>
              <event>
                <sub_title>increased creatinine</sub_title>
                <description>Maintenance phase</description>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="54"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>muscle spasms/cramps</sub_title>
                <description>Car phase</description>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>muscle weakness</sub_title>
                <description>Car phase</description>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>pain in legs</sub_title>
                <description>Car phase</description>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>hip pain</sub_title>
                <description>Car phase</description>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>back pain</sub_title>
                <description>Car phase</description>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>knee pain</sub_title>
                <description>Car phase</description>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>lower extremity pain</sub_title>
                <description>Car phase</description>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>muscle spasms/cramps</sub_title>
                <description>BiRD phase</description>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>hip pain</sub_title>
                <description>BiRD phase</description>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>bone pain</sub_title>
                <description>BiRD phase</description>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>muscle spasms/cramps</sub_title>
                <description>Maintenance phase</description>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="54"/>
              </event>
              <event>
                <sub_title>shoulder pain</sub_title>
                <description>Maintenance phase</description>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="54"/>
              </event>
              <event>
                <sub_title>rib pain</sub_title>
                <description>Maintenance phase</description>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="54"/>
              </event>
              <event>
                <sub_title>chest pain (muscular)</sub_title>
                <description>Maintenance phase</description>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="54"/>
              </event>
              <event>
                <sub_title>pain in legs</sub_title>
                <description>Maintenance phase</description>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="54"/>
              </event>
              <event>
                <sub_title>hip pain</sub_title>
                <description>Maintenance phase</description>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="54"/>
              </event>
              <event>
                <sub_title>back pain</sub_title>
                <description>Maintenance phase</description>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="54"/>
              </event>
              <event>
                <sub_title>arthralgias</sub_title>
                <description>Maintenance phase</description>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="54"/>
              </event>
              <event>
                <sub_title>neck pain</sub_title>
                <description>Maintenance phase</description>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="54"/>
              </event>
              <event>
                <sub_title>pain in foot</sub_title>
                <description>Maintenance phase</description>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="54"/>
              </event>
              <event>
                <sub_title>lower extremity pain</sub_title>
                <description>Maintenance phase</description>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="54"/>
              </event>
              <event>
                <sub_title>upper extremity pain</sub_title>
                <description>Maintenance phase</description>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="54"/>
              </event>
              <event>
                <sub_title>knee pain</sub_title>
                <description>Maintenance phase</description>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="54"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>peripheral neuropathy</sub_title>
                <description>Car phase</description>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>tremor</sub_title>
                <description>Car phase</description>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>anxiety/stress</sub_title>
                <description>Car phase</description>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>dizziness / lightheaded</sub_title>
                <description>Car phase</description>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>paresthesias</sub_title>
                <description>Car phase</description>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>forgetful</sub_title>
                <description>Car phase</description>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>dysgeusia</sub_title>
                <description>Car phase</description>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>headache</sub_title>
                <description>Car phase</description>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>irritability</sub_title>
                <description>Car phase</description>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>agitation</sub_title>
                <description>Car phase</description>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>concentration impairment</sub_title>
                <description>Car phase</description>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>peripheral neuropathy</sub_title>
                <description>BiRD phase</description>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>tremor</sub_title>
                <description>BiRD phase</description>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>dizziness / lightheaded</sub_title>
                <description>BiRD phase</description>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>parethesias</sub_title>
                <description>BiRD phase</description>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>dysgeusia</sub_title>
                <description>BiRD phase</description>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>irritability</sub_title>
                <description>BiRD phase</description>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>peripheral neuropathy</sub_title>
                <description>Maintenance phase</description>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="54"/>
              </event>
              <event>
                <sub_title>dizziness / lightheaded</sub_title>
                <description>Maintenance phase</description>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="54"/>
              </event>
              <event>
                <sub_title>headache</sub_title>
                <description>Maintenance phase</description>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="54"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>depression</sub_title>
                <description>Car phase</description>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>anxiety/stress</sub_title>
                <description>Maintenance phase</description>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="54"/>
              </event>
              <event>
                <sub_title>depression</sub_title>
                <description>Maintenance phase</description>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="54"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>low eGFR</sub_title>
                <description>Car phase</description>
                <counts group_id="E1" subjects_affected="37" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>genitourinary frequency</sub_title>
                <description>Car phase</description>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>low eGFR</sub_title>
                <description>BiRD phase</description>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>genitourinary frequency</sub_title>
                <description>Maintenance phase</description>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="54"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnea</sub_title>
                <description>Car phase</description>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>cough</sub_title>
                <description>Car phase</description>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>sinus congestion</sub_title>
                <description>Car phase</description>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>sore throat</sub_title>
                <description>Car phase</description>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>dyspnea</sub_title>
                <description>BiRD phase</description>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>lung infection</sub_title>
                <description>BiRD phase</description>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>cough</sub_title>
                <description>BiRD phase</description>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>sinus congestion</sub_title>
                <description>BiRD phase</description>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>lung infection</sub_title>
                <description>Maintenance phase</description>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="54"/>
              </event>
              <event>
                <sub_title>cough</sub_title>
                <description>Maintenance phase</description>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="54"/>
              </event>
              <event>
                <sub_title>sore throat</sub_title>
                <description>Maintenance phase</description>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="54"/>
              </event>
              <event>
                <sub_title>sinus congestion</sub_title>
                <description>Maintenance phase</description>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="54"/>
              </event>
              <event>
                <sub_title>allergic rhinitis</sub_title>
                <description>Maintenance phase</description>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="54"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>rash</sub_title>
                <description>Car phase</description>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>rash</sub_title>
                <description>BiRD phase</description>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>pruritus</sub_title>
                <description>BiRD phase</description>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>rash</sub_title>
                <description>Maintenance phase</description>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="54"/>
              </event>
              <event>
                <sub_title>skin darknening</sub_title>
                <description>Maintenance phase</description>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="54"/>
              </event>
              <event>
                <sub_title>pruritus</sub_title>
                <description>Maintenance phase</description>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="54"/>
              </event>
              <event>
                <sub_title>dry skin</sub_title>
                <description>Maintenance phase</description>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="54"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>edema</sub_title>
                <description>Car phase</description>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>hypertension</sub_title>
                <description>Car phase</description>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>fever</sub_title>
                <description>Car phase</description>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>edema</sub_title>
                <description>BiRD phase</description>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>cushingoid appearance</sub_title>
                <description>BiRD phase</description>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>edema</sub_title>
                <description>Maintenance phase</description>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="54"/>
              </event>
              <event>
                <sub_title>hypertension</sub_title>
                <description>Maintenance phase</description>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="54"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Jennifer Hess</name_or_title>
      <organization>Weill Cornell Medicine</organization>
      <phone>6469629440</phone>
      <email>jmh2004@med.cornell.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

